Fund Holdings — Sands Capital Alternatives, LLC

Total Portfolio Value:
$355.77M
Total Bought:
$37.03M
Total Sold:
$56.45M
Net Transaction:
-$19.42M
Notable People:
Sands Capital Management, Lp, Erin Elizabeth Soule
Securities
▲▼
SharesValue
Q2 2024
▲▼
Q3 2024
▲▼
Change
▲▼
Q2 2024
▲▼
Q3 2024
▲▼
Weight (%)
▲▼
Change
▲▼
Klaviyo, Inc.COM SER A(KVYO)3,516,2213,515,325-896$87.52M$124.37M34.96%+$36.85M
Nu Holdings Ltd.CL A(NU)7,328,2945,498,802-1,829,492$94.46M$75.06M21.10%-$19.40M
DoorDash, Inc.CL A(DASH)423,091423,338+247$46.02M$60.42M16.98%+$14.40M
BioAge Labs, Inc.(BIOA)01,086,353+1,086,353$0$22.60M6.35%+$22.60M
Acrivon Therapeutics Inc2,122,6052,122,6050$12.31M$14.86M4.18%+$2.55M
UiPath, Inc.CL A(PATH)1,155,2461,155,2460$14.65M$14.79M4.16%+$138.6K
Snowflake Inc.CL A(SNOW)108,304108,3040$14.63M$12.44M3.50%-$2.19M
10x Genomics, Inc.CL A(TXG)481,770481,7700$9.37M$10.88M3.06%+$1.51M
Acumen Pharmaceuticals, Inc.(ABOS)3,417,0753,417,0750$8.27M$8.47M2.38%+$205.0K
Tarsus Pharmaceuticals, Inc.(TARS)170,000170,0000$4.62M$5.59M1.57%+$970.7K
Candel Therapeutics, Inc.(CADL)405,837405,8370$2.52M$2.81M0.79%+$296.3K
Taysha Gene Therapies, Inc.(TSHA)724,873724,8730$1.62M$1.46M0.41%-$166.7K
908 Devices Inc.(MASS)237,258237,2580$1.22M$823.3K0.23%-$398.6K
Spruce Biosciences Inc787,007787,0070$409.2K$369.9K0.10%-$39.4K
Coupang, Inc.CL A(CPNG)11,93111,9310$250.0K$292.9K0.08%+$43.0K
Datadog, Inc.CL A(DDOG)1,0151,406+391$131.6K$161.8K0.05%+$30.1K
Samsara Inc.CL A(IOT)4,2393,172-1,067$142.9K$152.6K0.04%+$9.8K
Toast, Inc.CL A(TOST)4,9454,453-492$127.4K$126.1K0.04%-$1.4K
CrowdStrike Holdings, Inc.CL A(CRWD)2212210$84.7K$62.0K0.02%-$22.7K
GitLab Inc.CL A(GTLB)6586580$32.7K$33.9K0.01%+$1.2K
Absci Corporation57,8040-57,804$178.0K$0—-$178.0K
Page 1 of 1
Sands Capital Alternatives, LLC — 13F Holdings — Q3 2024 | TickerTrail